RT Journal Article
SR Electronic
T1 708 A phase 1/2 study of rinatabart sesutecan (PRO1184), a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP A803
OP A803
DO 10.1136/jitc-2023-SITC2023.0708
VO 11
IS Suppl 1
A1 Call, Justin A
A1 Anderson, Ian
A1 Winer, Ira
A1 Orr, Douglas
A1 Yeku, Oladapo
A1 Richardson, Debra L
A1 Zhang, Jian
A1 Lee, Elizabeth
A1 Konecny, Gottfried
A1 Li, Ning
A1 Patel, Sandip P
A1 Wu, Lin
A1 Wang, Jing
A1 Zhang, Jun
A1 Cheng, Ying
A1 Wu, Xiaohua
A1 Hunder, Naomi
A1 Lu, Lian
A1 Ma, Sharon
A1 Song, Eric
A1 Hamilton, Erika
YR 2023
UL http://jitc.bmj.com/content/11/Suppl_1/A803.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.